Hyundai Bioscience announced that its drug XAFTY® has a low IC50 value of 0.125 μM against Ebola, indicating strong antiviral efficacy, even better than its effect on COVID-19. The drug has proven safety from Phase 2/3 COVID-19 and Dengue clinical trials, with no severe adverse events reported. XAFTY® also shows promising antiviral activity against Hantavirus-related viruses, making it a candidate for immediate use in outbreak situations. The company has sufficient stock ready for deployment to affected areas.
At Google Next 2026, Google Cloud Security used Instruqt's hands-on platform to train over 150 practitioners on Agentic AI capabilities. Participants built their own AI agents in dedicated Google Cloud Vertex AI environments, gaining practical experi...
Last week, large-cap stocks in sectors like technology, electric vehicles, data centers, and healthcare experienced declines due to weak earnings guidance, regulatory worries, rising bond yields, and increased competition. Notable losers included Int...
Sui Network experienced a 60% surge in daily transactions, processing 4.38 million in 24 hours with a fast 79 ms block time. Its market cap stands at $4.11 billion, over five times Aptos' $757 million, while Sui's DeFi total value locked (TVL) is $2....
The University of Michigan's final May consumer sentiment index fell to a record low of 44.8, signaling deep pessimism among Americans despite the stock market's strong performance with the S&P 500 up 9% year-to-date. Inflation expectations rose, wit...
Algorand's blockchain confirms transactions at the protocol level, making them irreversible once confirmed. This feature provides settlement certainty crucial for institutions, humanitarian programs, and emerging financial systems, unlike many blockc...
